U.S. Semiconductors Stock News

If you are wondering whether Synopsys at around US$464.85 is priced for opportunity or already reflects high expectations, the key is to understand what different valuation tools actually say about the stock. Over shorter periods the picture has been mixed, with the share price down about 2.3% over the last week, down 7.8% over the last month, down 3.2% year to date, and down 4.4% over the last year. The 3 year and 5 year returns sit at 5.9% and 76.7% respectively. Recent coverage of...

Keel Infrastructure (NasdaqGM:KEEL) has completed an upsized US$400 million convertible senior notes offering, above the initial US$350 million target. The transaction is intended to fund capped call arrangements and support expansion of data center projects for AI and high performance computing workloads. The offering adds financial flexibility as Keel continues its shift from Bitcoin mining toward broader digital infrastructure. Keel is positioning itself as a digital infrastructure...

For investors wondering whether Brookfield Infrastructure at around US$41.31 offers value or is asking too much for its future, this breakdown is designed to help frame that question in a clear, practical way. The stock has been slightly softer over the last week, with a 0.5% decline, but has gained 4.6% over the past month. Year to date it is down 8.8% and it is up 5.7% over the last year, with a 2.1% decline over three years and a 7.3% gain over five years. Recent price moves sit against a...

Recent sales update puts Buckle’s latest momentum in focus Buckle (BKE) has drawn fresh attention after its latest trading statement showed comparable store net sales rising 2.2% for the recent 4 week period and 4.4% year to date. See our latest analysis for Buckle. Despite the recent sales update and a reaffirmed quarterly dividend, Buckle’s share price has pulled back, with a 30 day share price return down 17.84% and year to date share price return down 16.78%. In contrast, the 5 year total...

Match Group (MTCH) is back in focus after reports of falling demand, weaker customer acquisition, and a sharp drop in average revenue per user over the past two years, which points to tougher sales conditions. See our latest analysis for Match Group. The stock has pulled back recently, with a 1-month share price return down 9.42% and a 7-day share price return down 4.73%. However, the 90-day share price return of 12.96% and 1-year total shareholder return of 10.67% suggest earlier momentum...

In recent days, 10x Genomics experienced an extended winning streak in its stock, lifting its market value by about US$1.10 billion even as commentators highlighted ongoing weakness in operating performance and financial condition. This sharp rerating, coming despite concerns about fundamentals and valuation, raises questions about how much of the positive sentiment is grounded in the company’s underlying business trajectory. We’ll now examine how this momentum-driven rally, despite weak...

PriceSmart, Inc. recently opened its sixth warehouse club in the Dominican Republic on a five-acre site in La Romana, bringing its total footprint to 57 clubs across 12 countries and one U.S. territory. This latest opening, alongside planned new clubs in Jamaica, Costa Rica, and Guatemala, highlights PriceSmart’s continued emphasis on regional expansion and membership-driven growth. Next, we’ll examine how PriceSmart’s strong quarterly performance and continued club expansion, including La...

Aurinia Pharmaceuticals (NasdaqGM:AUPH) reported new AURORA 1 Phase 3 data at EULAR 2026 showing LUPKYNIS reduced the risk of renal events or death in lupus nephritis. The findings were presented at a major international rheumatology congress, putting fresh clinical evidence for LUPKYNIS in front of global specialists. Tang Capital Management increased its stake in Aurinia, and senior company executives acquired additional shares. Aurinia focuses on therapies for autoimmune kidney disease,...

Recent performance snapshot United Natural Foods (UNFI) has drawn fresh attention after a period of strong share price movement, with the stock up 4.8% in the past day and 8.1% over the past week. Over the past month the stock has returned 7.2%, while the past 3 months show a much larger gain of about 52%. Year to date, United Natural Foods has returned 66.1%, and over the past year the total return is 99.3%. Looking further back, the 3 year total return is very large at about 17x, while the...

Recent returns and business context for KKR (KKR) KKR (KKR) has drawn investor attention after a mixed stretch of returns, with the stock down over the past month but higher over the past 3 months, set against a backdrop of declining annual revenue and higher net income. See our latest analysis for KKR. Short term momentum has softened, with the stock down 7.33% on a 1 month share price basis and lower year to date, while the 3 year total shareholder return of 72.84% still points to a strong...

Byline Bancorp (BY) has moved employee ownership and incentives to the forefront by filing a roughly $63.4 million shelf registration tied to its ESOP, alongside fresh approvals for expanded share based compensation plans. See our latest analysis for Byline Bancorp. The ESOP related shelf registration and refreshed incentive plans come as Byline Bancorp’s share price has moved to $33.78, with a 90 day share price return of 9.6% and a 1 year total shareholder return of 30.29%, signalling firm...

Conference spotlight following strong Q1 revenue jump BGC Group (BGC) is heading into its June 4 appearance at the Piper Sandler Global Exchange and Fintech Conference after reporting a 44% Q1 revenue increase, supported by organic growth, acquisitions, and electronic trading. See our latest analysis for BGC Group. BGC Group’s recent Q1 update lands after a strong run, with the share price up 16.27% over 90 days and the 3-year total shareholder return at 133.66%, suggesting positive momentum...

Gilead Sciences (NasdaqGS:GILD) has closed the acquisition of Ouro Medicines, bringing a clinical-stage BCMAxCD3 T cell engager, gamgertamig, into its pipeline. The deal expands Gilead's inflammation portfolio into autoimmune diseases, focused on severe antibody mediated orphan conditions. This move adds a late stage autoimmune asset alongside existing franchises in liver disease and oncology, including Livdelzi and Trodelvy. Gilead Sciences, trading at around $129.16, has seen its stock up...

Nvidia’s latest Computex keynote put AI demand back in the spotlight, and Lattice Semiconductor (LSCC) caught a wave of that enthusiasm as investors reconsidered the stock’s role in the broader AI hardware supply chain. See our latest analysis for Lattice Semiconductor. That enthusiasm sits alongside a sharp recent pullback, with the stock falling 10.76% on a 1-day share price return basis and 7.83% over 7 days, after a strong run that left its 90-day share price return at 58.58% and 1-year...

SoFi Technologies (NasdaqGS:SOFI) is the subject of a class-action investigation following a report accusing the company of aggressive financial reporting practices. The investigation focuses on potential regulatory and legal risks and raises questions about the transparency of SoFi's reported financials. These allegations come at a time when SoFi is already in the spotlight with recent share price moves and active retail investor interest. For investors tracking NasdaqGS:SOFI, this...

In early June 2026, Astera Labs, Inc. expanded its Taiwan operations and Cloud-Scale Interop Lab to be closer to the semiconductor supply chain, enhancing engineering collaboration and system validation with partners including AMD, Arm, Intel, NVIDIA, and major Taiwan ODMs. This move tightens Astera Labs’ integration into rack-scale AI system design and testing, potentially shortening customers’ development cycles and embedding its Scorpio fabric switches more deeply into next-generation AI...

Investors may be wondering if Middleby stock at around US$154.93 offers good value today, or if they are paying up mainly for the story. Over the past month the share price has risen 8.7%, while the 1-year return sits at 5.2% and the 5-year return shows a decline of 8.6%. This may hint at shifting views on both its potential and its risks. Recent coverage of Middleby has focused on its position in the capital goods space and investor interest in how its business model compares with peers...

In its recent third-quarter fiscal 2026 update, Amcor reported adjusted earnings in line with expectations, higher net sales supported by the Berry acquisition, improved margins, and a reduced full-year outlook tied to inventory and supply issues linked to Middle East conflict. At the same time, Amcor has been expanding its healthcare packaging footprint with new cleanroom certification in Puerto Rico and a manufacturing expansion in India, underscoring a growing emphasis on higher-value...

Recent share performance and what it might mean Illumina (ILMN) has drawn fresh attention after a strong run in recent months, with the stock up about 14% over the past month and roughly 30% over the past 3 months. See our latest analysis for Illumina. At a share price of US$162.32, Illumina’s recent 30 day share price return of 13.84% and 90 day return of 30.25% sit alongside a 1 year total shareholder return of 96.37%, although the 3 and 5 year total shareholder returns remain negative. If...

Kratos Defense & Security Solutions (KTOS) is caught in a tug of war between solid contract momentum and macro headwinds, as sector wide selling on higher rates and lower geopolitical risk premiums pressures the stock. See our latest analysis for Kratos Defense & Security Solutions. After strong contract news and an earnings beat, Kratos’ share price has recently given back ground, with a 1-day share price return down 7.7% and a 90-day share price return down 32.7%. At the same time, the...

Investors may be wondering whether IDACORP at about US$141 per share is offering good value right now, or if the easy money has already been made. The stock is up 11.0% year to date and 26.0% over the past year, although it has slipped 1.9% over the last month and inched 0.8% higher over the last week. Recent coverage has focused on IDACORP as an established electric utility, with investors weighing regulated earnings, capital needs and its role in regional power infrastructure. That...

Bread Financial Holdings recently filed two shelf registrations for employee stock ownership plan offerings totaling about US$218.55 million, covering 2,523,653 common shares. These ESOP-related filings highlight how employee ownership remains an important tool in Bread Financial’s capital planning alongside new partnerships and buybacks. Next, we’ll look at how the Ford partnership, alongside these ESOP moves, may influence Bread Financial’s existing investment narrative. The future of work...

Recent performance context for Ligand Pharmaceuticals (LGND) Without a specific news event driving headlines today, Ligand Pharmaceuticals (LGND) still gives investors some fresh data points to consider, from recent share performance to reported revenue and net income figures. See our latest analysis for Ligand Pharmaceuticals. At a share price of $237.00, Ligand Pharmaceuticals has shown solid momentum, with a 17.38% 90 day share price return and a 123.61% 1 year total shareholder return...

If you are wondering whether NOV at around US$20.14 still offers value or if most of the opportunity is already priced in, you are asking the right question. The stock has returned 0.9% over the past week, is roughly flat over the last month with a 0.2% decline, and sits on a 22.7% year to date gain and 63.7% return over the past year. This naturally raises questions about how much upside or risk is now on the table. Recent coverage of NOV has focused on its role in the energy equipment and...